{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003949","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.346067+00:00","generated_at":"2026-05-16T17:05:15.564269+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026","bullets":["Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.","Regulatory submissions planned to Israel Ministry of Health and Germany's BfArM ahead of Phase 2/3 trial.","Phase 2/3 clinical trial in locally advanced pancreatic cancer (LAPC) expected to initiate in Q2 2026.","CRO partner for the trial has been secured; SIL204 targets mutant KRAS oncogenes via siRNA."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003949","json":"https://secwatch.observer/filing/0001178913-25-003949.json","markdown":"https://secwatch.observer/filing/0001178913-25-003949.md","text":"https://secwatch.observer/filing/0001178913-25-003949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/0001178913-25-003949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/zk2534066.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:05:15.564269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}